For many people, oral supplements can be a good maintenance tool
Adverse effects included amyloid-related imaging problems (24% donanemab vs
Phase 2 data showed 24.2% weight loss at 48 weeks with no plateau, and Phase 3 TRIUMPH-4 data confirmed continued loss to 28.7% at 68 weeks
However, if you find that the lower 1.7 mg/week or 2.4mg/week strengths are effective for you, or you're experiencing side effects with the 7.2 mg dose, you can stick to the lower dose

Dyoung, accessed February 2, 2026, Revision of the legislation on supplementary protection certificates for plant protection products (RECAST) | Legislative Train Schedule European Parliament, accessed February 2, 2026, Implementation Of The Pharmaceutical Strategy For Europe And The Intellectual Property Action Plan Part 2 Maiwald GmbH, accessed February 2, 2026, A to Z: Drugs in Highlight Revisited Secerna, accessed February 2, 2026, More Than a Feeling: UPC, Rewriting the Score for Pharma at BIO 2025 Wolters Kluwer, accessed February 2, 2026, Beijing Supreme Peoples Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data Eagle IP, accessed February 2, 2026, China delivers a win for Novo Nordisk on semaglutide IP pharmaphorum, accessed February 2, 2026, Chinese drugmakers prep for looming semaglutide generics horizon, accessed February 2, 2026, Ozempics Patent Protection Starts to Expire in 2026